Atnaujinkite slapukų nuostatas

Pharmacology: Connections to Nursing Practice 3rd edition [Kietas viršelis]

3.89/5 (20 ratings by Goodreads)
,
  • Formatas: Hardback, 1440 pages, aukštis x plotis x storis: 280x220x50 mm, weight: 2866 g
  • Išleidimo metai: 12-Feb-2015
  • Leidėjas: Pearson
  • ISBN-10: 0133923614
  • ISBN-13: 9780133923612
Kitos knygos pagal šią temą:
Pharmacology: Connections to Nursing Practice 3rd editionDidesnis paveikslėlis
  • Formatas: Hardback, 1440 pages, aukštis x plotis x storis: 280x220x50 mm, weight: 2866 g
  • Išleidimo metai: 12-Feb-2015
  • Leidėjas: Pearson
  • ISBN-10: 0133923614
  • ISBN-13: 9780133923612
Kitos knygos pagal šią temą:
Pastovi nuoroda: https://www.kriso.lt/db/9780133923612.html
Raktažodžiai:

NOTE: You are purchasing a standalone product; MyNursingLab does not come packaged with this content. If you would like to purchase both the physical text and MyNursingLab search for 0134162978 / 9780134162973Pharmacology: Connections to Nursing Practice Plus MyNursingLab with Pearson eText -- Access Card Package

Package consists of:

  • 0133923614 / 9780133923612 Pharmacology: Connections to Nursing Practice
  • 0134160924 / 9780134160924 MyNursingLab with Pearson eText -- Access Card -- forPharmacology: Connections to Nursing Practice

MyNursingLab should only be purchased when required by an instructor.

A patient-centered approach to pharmacology

Pharmacology: Connections to Nursing Practice tightly links pharmacology to nursing practice and patient care, recognizing that for nurses, pharmacology is not an abstract academic discipline but rather a critical tool to prevent disease and promote healing and wellness. It offers unsurpassed features designed to illuminate connections between pharmacology and practice, from patient scenarios and practice applications to coverage of lifespan considerations, patient education, alternative therapies, and gender/cultural influences. Learning is simplified through the use of prototype drugs, as well as outstanding full-color illustrations. Organization by body systems (units) and diseases (chapters) places the drugs in context with how they are used therapeutically and connects pharmacology and pathophysiology to nursing care. The Third Edition covers 25 new medications approved by the FDA since the previous edition, a new chapter on Individual Variations in Drug Responses, and updated review questions that better prepare students for exams.

UNIT 1 Fundamental Principles of Pharmacology
Chapter 1 Introduction to Pharmacology: Concepts and Connections
2(10)
Brief History of Pharmacology
3(1)
Pharmacology: The Study of Medicines
4(1)
Characteristics of an Ideal Drug
5(1)
Classification of Drugs
5(1)
Drug Prototypes
6(1)
Naming Drugs
7(1)
Connecting Pharmacology to Clinical Nursing Practice
8(4)
Chapter 2 Drug Regulations
12(12)
Patent Medicines
13(1)
Brief History of Drug Legislation
13(2)
Drug Standards
15(1)
The U.S. Food and Drug Administration
16(1)
Drug Approval
17(1)
Changes to the Drug Approval Process
18(1)
Prescription and Over-the-Counter Drugs
19(1)
Drug Schedules
20(1)
Prescriptive Authority for Nurses
20(4)
Chapter 3 Pharmacokinetics
24(18)
Introduction to Pharmacokinetics
25(2)
Primary Processes of Pharmacokinetics
27(1)
Route of Administration
27(3)
Drug Concentration and Dose
30(1)
GI Tract Environment
30(1)
Blood flow to the Absorption Site
31(1)
Drug Ionization
31(1)
Drug Interactions
31(5)
Surface Area
31
Time--Response Relationships
36(6)
Chapter 4 Pharmacodynamics
42(10)
Interpatient Variability
43(1)
Therapeutic Index
44(1)
Dose--Response Relationship
44(1)
Potency and Efficacy
45(1)
Receptor Theory
46(2)
Agonists and Antagonists
48(1)
Pharmacogenetics
48(4)
Chapter 5 Adverse Drug Effects and Drug Interactions
52(14)
Adverse Drug Effects
53(5)
Drug Interactions
58(8)
Chapter 6 Medication Errors and Risk Reduction
66(13)
Medication Errors and Their Impact on Health Care
67(1)
Factors Contributing to Medication Errors
67(3)
Drug Names and Medication Errors
70(1)
Reporting Medication Errors
70(2)
Strategies for Reducing Medication Errors
72(7)
Chapter 7 The Role of Complementary and Alternative Therapies in Pharmacotherapy
79(13)
Types of Complementary and Alternative Therapies
80(1)
History of Herbal Therapies
81(1)
Standardization of Herbal Products
82(2)
Dietary Supplement Regulation
84(1)
Herb--Drug Interactions
85(2)
Specialty Supplements
87(5)
UNIT 2 Pharmacology and the Nurse--Patient Relationship
Chapter 8 Pharmacotherapy During Pregnancy and Lactation
92(11)
Rationale for Drug Use During Pregnancy and Lactation
93(1)
Pharmacotherapy During Pregnancy
93(4)
Pharmacotherapy During Lactation
97(6)
Chapter 9 Pharmacotherapy of the Pediatric Patient
103(13)
Testing and Labeling of Pediatric Drugs
104(2)
Pharmacokinetic Variables in Pediatric Patients
106(1)
Pharmacologic Implications Associated with Growth and Development
107(2)
Medication Safety for Pediatric Patients
109(1)
Determining Pediatric Drug Dosages
110(1)
Adverse Drug Reactions in Children and Promoting Adherence
110(6)
Chapter 10 Pharmacotherapy of the Geriatric Patient
116(10)
Polypharmacy
117(1)
Physiological Changes Related to Aging
118(1)
Pharmacokinetic and Pharmacodynamic Changes in Older Adults
118(2)
Adherence and Drug Misuse Among Older Adults
120(1)
Adverse Drug Reactions in Older Adults
121(5)
Chapter 11 Individual Variations in Drug Responses
126(10)
Psychosocial Influences
127(1)
Cultural and Ethnic Variables
127(1)
Genetic Influences
128(2)
Gender Influences
130(6)
UNIT 3 Pharmacology of the Autonomic Nervous System
Chapter 12 Review of Neurotransmitters and the Autonomic Nervous System
136(13)
Overview of the Nervous System
137(1)
Structure and Function of the Autonomic Nervous System
138(2)
Synaptic Transmission
140(2)
Cholinergic Transmission
142(1)
Cholinergic Receptors and Neurotransmitters
142(1)
Termination of Acetylcholine Action
143(1)
Adrenergic Transmission
144(1)
Alpha-Adrenergic Receptors
145(1)
Beta-Adrenergic Receptors
145(1)
Termination of Norepinephrine Action
145(1)
Regulation of Autonomic Functions
146(1)
Classifying Autonomic Drugs
147(2)
Chapter 13 Cholinergic Agonists
149(14)
Cholinergic Receptors
150(2)
Muscarinic Agonists
152(1)
PROTOTYPE DRUG: Bethanechol (Urecholine)
153(2)
Pharmacotherapy of Myasthenia Gravis
155(2)
PROTOTYPE DRUG: Pyridostigmine (Mestinon, Regonol)
157(1)
Nicotinic Agonists
158(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Cholinergic Agonists
159(4)
Chapter 14 Cholinergic Antagonists
163(14)
Classification of Cholinergic Antagonists
164(1)
Muscarinic Antagonists
165(1)
PROTOTYPE DRUG: Atropine (Atropen)
166(2)
Nicotinic Antagonists: Ganglionic Blockers
168(1)
Nicotinic Antagonists: Neuromuscular Blockers
168(2)
PROTOTYPE DRUG: Succinylcholine (Anectine, Quelicin)
170(3)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Cholinergic (Muscarinic) Antagonists
173(4)
Chapter 15 Adrenergic Agonists
177(15)
Actions of Adrenergic Agonists
178(1)
Mechanisms of Action of Adrenergic Agonists
178(1)
Classification of Adrenergic Agonists
179(1)
Nonselective Adrenergic Agonists
180(1)
PROTOTYPE DRUG: Epinephrine (Adrenalin)
181(2)
Alpha-Adrenergic Agonists
183(1)
PROTOTYPE DRUG: Phenylephrine (Neo-Synephrine)
184(1)
Beta-Adrenergic Agonists
185(1)
PROTOTYPE DRUG: Isoproterenol (Isuprel)
186(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Adrenergic Agonists
187(5)
Chapter 16 Adrenergic Antagonists
192(16)
Actions of Adrenergic Antagonists
193(1)
Alpha-Adrenergic Antagonists
193(3)
PROTOTYPE DRUG: Prazosin (Minipress)
196(1)
Beta-Adrenergic Antagonists
197(2)
PROTOTYPE DRUG: Propranolol (Inderal, InnoPran XL)
199(2)
PROTOTYPE DRUG: Metoprolol (Lopressor, Toprol XL)
201(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Adrenergic Antagonists
203(5)
UNIT 4 Pharmacology of the Central Nervous System
Chapter 17 Review of the Central Nervous System
208(8)
Scope of Central Nervous System Pharmacology
209(1)
Neurons and Neurotransmission
210(1)
Structural Divisions of the Central Nervous System
211(2)
Functional Systems of the Central Nervous System
213(3)
Chapter 18 Pharmacotherapy of Anxiety and Sleep Disorders
216(23)
Anxiety Disorders
217(3)
Sleep Disorders
220(2)
Management of Anxiety and Sleep Disorders
222(2)
Pharmacotherapy of Anxiety and Insomnia
224(2)
PROTOTYPE DRUG: Lorazepam (Ativan)
226(3)
PROTOTYPE DRUG: Zolpidem (Ambien, Edluar, Others)
229(3)
PROTOTYPE DRUG: Phenobarbital (Luminal)
232(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Anxiety or Sleep Disorders
234(5)
Chapter 19 Pharmacotherapy of Mood Disorders
239(25)
Categories of Mood Disorders
240(1)
Major Depressive Disorder
240(1)
Pathophysiology of Depression
241(1)
Assessment of Depression
242(1)
Nonpharmacologic Therapies for Depression
243(1)
Pharmacotherapy of Depression
244(1)
Tricyclic Antidepressants
244(2)
PROTOTYPE DRUG: Imipramine (Tofranil)
246(2)
Selective Serotonin Reuptake Inhibitors
248(1)
PROTOTYPE DRUG: Fluoxetine (Prozac, Sarafem)
248(2)
Atypical Antidepressants
250(1)
PROTOTYPE DRUG: Venlafaxine (Effexor)
251(2)
Monoamine Oxidase Inhibitors
253(1)
PROTOTYPE DRUG: Phenelzine (Nardil)
254(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antidepressants
255(2)
Bipolar Disorder
257(1)
Drugs for Bipolar Disorder
257(1)
PROTOTYPE DRUG: Lithium Carbonate (Eskalith, Lithobid)
258(6)
Chapter 20 Pharmacotherapy of Psychoses
264(21)
Characteristics of Psychoses
265(1)
Symptoms of Schizophrenia
265(2)
Etiology of Schizophrenia
267(1)
Management of Psychoses
268(1)
Antipsychotic Drugs
269(1)
First-Generation Antipsychotics
270(2)
PROTOTYPE DRUG: Chlorpromazine
272(1)
PROTOTYPE DRUG: Haloperidol (Haldol)
273(1)
Second-Generation (Atypical) Antipsychotics
274(1)
PROTOTYPE DRUG: Risperidone (Risperdal)
274(3)
PROTOTYPE DRUG: Aripiprazole (Ability)
277(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antipsychotics
279(6)
Chapter 21 Pharmacotherapy of Degenerative Diseases of the Central Nervous System
285(24)
Degenerative Diseases of the Central Nervous System
286(1)
Parkinson's Disease
286(2)
Pharmacotherapy of Parkinson's Disease
288(1)
PROTOTYPE DRUG: Levodopa and Carbidopa (Sinemet, Parcopa)
289(2)
PROTOTYPE DRUG: Pramipexole (Mirapex)
291(3)
PROTOTYPE DRUG: Benztropine (Cogentin)
294(1)
Alzheimer's Disease
295(1)
Pharmacotherapy of Alzheimer's Disease
296(2)
PROTOTYPE DRUG: Donepezil (Aricept)
298(2)
Multiple Sclerosis
300(1)
PROTOTYPE DRUG: Interferon beta-1b (Betaseron, Extavia, Plegridy)
301(3)
Amyotrophic Lateral Sclerosis
304(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Neurodegenerative Disorders
304(5)
Chapter 22 Pharmacotherapy of Seizures
309(25)
Characteristics of Seizure Disorders
310(3)
Classification of Seizure Disorders
313(1)
Generalized Seizures
313(1)
Partial Seizures
314(3)
Antiepileptic Drugs
317(3)
PROTOTYPE DRUG: Diazepam (Valium)
320(2)
PROTOTYPE DRUG: Phenytoin (Dilantin, Phenytek)
322(1)
PROTOTYPE DRUG: Carbamazepine (Carbatrol, Tegretol, Others)
323(2)
PROTOTYPE DRUG: Ethosuximide (Zarontin)
325(1)
PROTOTYPE DRUG: Gabapentin (Neurontin)
326(1)
PROTOTYPE DRUG: Valproic Acid (Depacon, Depakene, Depakote)
326(1)
Other Miscellaneous Drugs
327(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Seizures
329(5)
Chapter 23 Pharmacotherapy of Muscle Spasms and Spasticity
334(16)
Etiology and Pathophysiology of Muscle Spasms and Spasticity
335(1)
Nonpharmacologic Therapies for Muscle Spasms and Spasticity
336(1)
Pharmacotherapy of Muscle Spasms
337(1)
PROTOTYPE DRUG: Cyclobenzaprine (Amrix, Flexeril)
338(3)
Pharmacotherapy of Muscle Spasticity
341(1)
PROTOTYPE DRUG: Dantrolene (Dantrium, Revonto)
342(3)
Skeletal Muscle Relaxants as Surgical Adjuncts
345(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Muscle Spasms and Spasticity
345(5)
Chapter 24 Central Nervous System Stimulants and Drugs for Attention Deficit/Hyperactivity Disorder
350(16)
Characteristics of Central Nervous System Stimulants
351(1)
Etiology and Pathophysiology of Attention Deficit/Hyperactivity Disorder
352(1)
Pharmacotherapy of Attention Deficit/Hyperactivity Disorder
353(2)
PROTOTYPE DRUG: Amphetamine and Dextroamphetamine (Adderall, Adderall XR)
355(2)
PROTOTYPE DRUG: Atomoxetine (Strattera)
357(1)
Pharmacotherapy of Narcolepsy
358(1)
PROTOTYPE DRUG: Modafinil (Provigil)
358(1)
Methylxanthines
359(1)
PROTOTYPE DRUG: Caffeine
359(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Central Nervous System Stimulants
361(5)
Chapter 25 Pharmacotherapy of Severe Pain and Migraines
366(28)
General Principles of Pain Management
367(5)
Pain Management with Opioids
372(4)
PROTOTYPE DRUG: Morphine Sulfate (Astramorph PF, Duramorph RF, Roxanol, Others)
376(3)
Pain Management with Nonopioids
379(1)
PROTOTYPE DRUG: Tramadol (Ultram, Others)
379(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Pain
380(4)
Pharmacotherapy with Opioid Antagonists
384(1)
Pharmacotherapy of Migraines
385(2)
PROTOTYPE DRUG: Sumatriptan (Imitrex, Others)
387(3)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Migraines
390(4)
Chapter 26 Anesthetics and Anesthesia Adjuncts
394(22)
Types of Anesthesia
395(1)
Principles of General Anesthesia
395(1)
Intravenous Anesthetics
396(1)
PROTOTYPE DRUG: Fentanyl (Sublimaze)
396(2)
PROTOTYPE DRUG: Midazolam (Versed)
398(1)
PROTOTYPE DRUG: Propofol (Diprivan)
399(2)
Inhalation Anesthetics
401(1)
PROTOTYPE DRUG: Nitrous Oxide
402(1)
PROTOTYPE DRUG: Isoflurane (Forane)
403(1)
Local Anesthetics
404(3)
CONNECTIONS: Nursing Practice Application Patients Receiving General Anesthesia
407(1)
PROTOTYPE DRUG: Procaine (Novocaine)
408(2)
PROTOTYPE DRUG: Lidocaine (Anestacon, Dilocaine, Xylocaine, Others)
410(1)
Adjuncts to Anesthesia
411(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Local Anesthesia
412(4)
Chapter 27 Pharmacology of Substance Abuse
416(24)
Fundamental Concepts of Substance Abuse
417(1)
Legislation of Controlled Substances
418(1)
Addiction and Dependence
418(1)
Tolerance
419(1)
Central Nervous System Depressants
420(1)
Sedatives and Antianxiety Drugs
421(1)
Opioids
421(1)
PROTOTYPE DRUG: Buprenorphine with naloxone (Suboxone, Zubsolv)
422(1)
Alcohol (Ethanol)
423(3)
PROTOTYPE DRUG: Disulfiram (Antabuse)
426(1)
Marijuana and Related Substances
426(1)
Hallucinogens
427(1)
LSD and Similar Hallucinogens
427(1)
Club Drugs and Miscellaneous Hallucinogens
428(1)
Central Nervous System Stimulants
429(1)
Amphetamines and Methylphenidate
429(1)
Cocaine
430(1)
Caffeine
431(1)
Nicotine
431(1)
PROTOTYPE DRUG: Varenicline (Chantix)
432(1)
Inhalants
432(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Substance Abuse Disorders
433(1)
Anabolic Steroids
434(6)
UNIT 5 Pharmacology of the Cardiovascular System
Chapter 28 Review of the Cardiovascular System
440(13)
Structure and Function of the Cardiovascular System
441(1)
Functions and Properties of Blood
441(3)
Cardiac Structure and Function
444(4)
Hemodynamics and Blood Pressure
448(5)
Chapter 29 Pharmacotherapy of Hyperlipidemia
453(20)
Types of Lipids and Lipoproteins
454(2)
Measurement and Control of Serum Lipids
456(2)
Drugs for Dyslipidemias
458(4)
PROTOTYPE DRUG: Atorvastatin (Lipitor)
462(2)
PROTOTYPE DRUG: Cholestyramine (Questran)
464(2)
PROTOTYPE DRUG: Gemfibrozil (Lopid)
466(1)
Miscellaneous Drugs for Dyslipidemias
467(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Hyperlipidemia
468(5)
Chapter 30 Pharmacotherapy with Calcium Channel Blockers
473(13)
Physiological Role of Calcium Channels in Muscle Contraction
474(1)
Types of Calcium Channels
475(1)
Consequences of Calcium Channel Blockade
475(1)
Classification of Calcium Channel Blockers
476(1)
PROTOTYPE DRUG: Nifedipine (Adalat CC, Procardia XL)
477(3)
PROTOTYPE DRUG: Verapamil (Calan, Isoptin, Verelan)
480(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Calcium Channel Blockers
482(4)
Chapter 31 Drugs Affecting the Renin-Angiotensin-Aldosterone System
486(15)
Components of the Renin-Angiotensin-Aldosterone System
487(2)
Physiological Actions of the Renin-Angiotensin-Aldosterone System
489(1)
Drugs Affecting the Renin-Angiotensin-Aldosterone System
490(1)
PROTOTYPE DRUG: Lisinopril (Prinivil, Zestril)
491(2)
PROTOTYPE DRUG: Losartan (Cozaar)
493(3)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
496(5)
Chapter 32 Diuretic Therapy and the Pharmacotherapy of Renal Failure
501(20)
Review of Renal Physiology
502(2)
Pharmacotherapy for Patients with Renal Failure
504(1)
Diuretic Therapy
505(1)
Loop (High-Ceiling) Diuretics
506(2)
PROTOTYPE DRUG: Furosemide (Lasix)
508(1)
Thiazide and Thiazide-Like Diuretics
509(1)
PROTOTYPE DRUG: Hydrochlorothiazide (Microzide)
510(1)
Potassium-Sparing Diuretics
511(1)
PROTOTYPE DRUG: Spironolactone (Aldactone)
512(1)
Osmotic Diuretics
513(1)
PROTOTYPE DRUG: Mannitol (Osmitrol)
514(1)
Carbonic Anhydrase Inhibitors
515(1)
PROTOTYPE DRUG: Acetazolamide (Diamox)
515(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Diuretics
516(5)
Chapter 33 Pharmacotherapy of Fluid Imbalance, Electrolyte, and Acid--Base Disorders
521(20)
Principles of Fluid Balance
522(1)
Fluid Replacement Agents
523(2)
PROTOTYPE DRUG: Normal Serum Albumin (Albuminar, Plasbumin, Others)
525(1)
PROTOTYPE DRUG: 5% Dextrose in Water (D5W)
526(1)
PROTOTYPE DRUG: Dextran 40 (Gentran 40, Others)
527(1)
Physiology of Electrolytes
528(1)
Pharmacotherapy of Electrolyte Imbalances
528(2)
PROTOTYPE DRUG: Sodium Chloride (NaCl)
530(1)
PROTOTYPE DRUG: Potassium Chloride (KCl)
531(1)
PROTOTYPE DRUG: Magnesium Sulfate (MgSO4)
532(1)
Pharmacotherapy of Acid--Base Imbalances
533(1)
PROTOTYPE DRUG: Sodium Bicarbonate
534(1)
PROTOTYPE DRUG: Ammonium Chloride
535(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Fluid and Electrolyte Imbalances
536(5)
Chapter 34 Pharmacotherapy of Hypertension
541(18)
Etiology and Pathogenesis of Hypertension
542(1)
Nonpharmacologic Management of Hypertension
543(1)
Guidelines for the Management of Hypertension
543(1)
Pharmacotherapy of Hypertension
544(1)
Initial Drug of Choice
544(1)
Adding Drugs to the Antihypertensive Regimen
544(2)
Enhancing Patient Adherence
546(1)
Antihypertensives in African Americans
546(1)
Drug Classes for Hypertension
546(5)
PROTOTYPE DRUG: Hydralazine (Apresoline)
551(1)
Management of Hypertensive Emergency
552(1)
PROTOTYPE DRUG: Nitroprusside Sodium (Nitropress)
552(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Direct Vasodilators
554(5)
Chapter 35 Pharmacotherapy of Angina Pectoris and Myocardial Infarction
559(19)
Pathophysiology of Myocardial Ischemia
560(1)
Myocardial Oxygen Supply
560(1)
Myocardial Oxygen Demand
560(1)
Etiology of Coronary Artery Disease
560(1)
Pathophysiology of Angina Pectoris
561(1)
Nonpharmacologic Therapy of Coronary Artery Disease
562(1)
Pharmacologic Management of Angina Pectoris
562(2)
Drug Classes for Angina Pectoris
564(1)
PROTOTYPE DRUG: Nitroglycerin (Nitrostat, Nitro-Bid, Nitro-Dur, Others)
565(1)
PROTOTYPE DRUG: Atenolol (Tenormin)
566(1)
Pathophysiology of Myocardial Infarction
567(2)
Pharmacologic Management of Myocardial Infarction
569(1)
Aspirin
569(2)
Anticoagulants and Antiplatelet Drugs
571(1)
Nitrates
572(1)
Beta-Adrenergic Blockers
572(1)
Angiotensin-Converting Enzyme Inhibitors
572(1)
Pain Management
572(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Organic Nitrates for Angina and Myocardial Infarction
573(5)
Chapter 36 Pharmacotherapy of Heart Failure
578(18)
Etiology of Heart Failure
579(1)
Pathophysiology of Heart Failure
579(1)
Ventricular Hypertrophy
579(1)
Activation of the Sympathetic Nervous System
580(1)
Increased Plasma Volume and Preload
581(1)
Natriuretic Peptides and Neurohumoral factors
581(1)
Pharmacologic Management of Heart Failure
581(1)
Drugs for Heart Failure
582(5)
PROTOTYPE DRUG: Digoxin (Lanoxin, Lanoxicaps)
587(2)
PROTOTYPE DRUG: Milrinone (Primacor)
589(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Heart Failure
591(5)
Chapter 37 Pharmacotherapy of Dysrhythmias
596(18)
Etiology of Dysrhythmias
597(1)
Phases and Measurement of the Cardiac Action Potential
597(2)
Classification of Dysrhythmias
599(1)
General Principles of Dysrhythmia Management
600(1)
Drugs for Dysrhythmias
601(1)
Sodium Channel Blockers: Class I
601(3)
PROTOTYPE DRUG: Procainamide
604(2)
Beta-Adrenergic Antagonists: Class II
606(1)
Potassium Channel Blockers: Class III
607(1)
PROTOTYPE DRUG: Amiodarone (Cordarone, Pacerone)
607(2)
Calcium Channel Blockers: Class IV
609(1)
Miscellaneous Antidysrhythmics
609(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Dysrhythmias
610(4)
Chapter 38 Pharmacotherapy of Coagulation Disorders
614(28)
Disorders of Hemostasis
615(2)
Overview of Coagulation Modifiers
617(1)
Anticoagulants
617(2)
PROTOTYPE DRUG: Heparin
619(2)
PROTOTYPE DRUG: Warfarin (Coumadin)
621(2)
PROTOTYPE DRUG: Dabigatran (Pradaxa)
623(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Anticoagulants
624(2)
Antiplatelet Drugs
626(1)
PROTOTYPE DRUG: Clopidogrel (Plavix)
627(2)
PROTOTYPE DRUG: Abciximab (ReoPro)
629(1)
Drugs for Intermittent Claudication
630(1)
Thrombolytics
631(1)
PROTOTYPE DRUG: Alteplase (Activase)
632(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Thrombolytics
633(2)
Hemostatics
635(1)
PROTOTYPE DRUG: Aminocaproic Acid (Amicar)
635(1)
Drugs for Hemophilia
636(22)
von Willebrand's Disease
658
Chapter 39 Pharmacotherapy of Hematopoietic Disorders
642(22)
Physiology of Hematopoiesis
643(1)
Hematopoietic Growth Factors
643(1)
PROTOTYPE DRUG: Epoetin Alfa (Epogen, Procrit)
644(2)
PROTOTYPE DRUG: Filgrastim (Neupogen)
646(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Erythropoietin
647(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Colony-Stimulating Factors
649(2)
PROTOTYPE DRUG: Oprelvekin (Neumega)
651(1)
Classification of Anemias
652(1)
Antianemic Drugs
653(2)
PROTOTYPE DRUG: Ferrous Sulfate (Feosol, Feostat, Others)
655(3)
PROTOTYPE DRUG: Cyanocobalamin (Nascobal)
658(6)
UNIT 6 Pharmacology of Body Defenses
Chapter 40 Review of Body Defenses and the Immune System
664(8)
Organization of the Lymphatic System
665(1)
Innate (Nonspecific) Body Defenses
665(2)
Inflammation
667(1)
Specific (Adaptive) Body Defenses
668(1)
Humoral Immune Response
669(1)
Cell-Mediated Immune Response
670(2)
Chapter 41 Pharmacotherapy of Inflammation and Fever
672(17)
Pathophysiology of Inflammation and Fever
673(1)
Pharmacotherapy of Inflammation
673(1)
Nonsteroidal Anti-Inflammatory Drugs
674(1)
Salicylates
674(2)
PROTOTYPE DRUG: Aspirin (Acetylsalicylic Acid)
676(3)
Ibuprofen-Like Drugs
679(1)
PROTOTYPE DRUG: Ibuprofen (Advil, Motrin, Others)
679(3)
Cyclooxygenase-2 Inhibitors
682(1)
PROTOTYPE DRUG: Celecoxib (Celebrex)
682(1)
Antipyretic and Analgesic Drugs
683(1)
PROTOTYPE DRUG: Acetaminophen (Tylenol)
683(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Inflammation and Fever
685(4)
Chapter 42 Immunostimulants and Immunosuppressants
689(20)
Immunostimulants
690(1)
PROTOTYPE DRUG: Interferon Alfa-2b (Intron A)
691(3)
PROTOTYPE DRUG: Aldesleukin (Proleukin)
694(1)
Immunosuppressants
695(3)
PROTOTYPE DRUG: Cyclosporine (Gengraf, Neoral, Sandimmune)
698(2)
PROTOTYPE DRUG: Azathioprine (Azasan, Imuran)
700(3)
PROTOTYPE DRUG: Basiliximab (Simulect)
703(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Immunomodulators
704(5)
Chapter 43 Immunizing Agents
709(21)
Discovery of Vaccines
710(1)
Vaccines and the Immune System
710(1)
Types of Vaccines
711(1)
General Principles of Vaccine Administration
712(1)
Active Immunity: Bacterial Immunizations
712(1)
Diphtheria
713(1)
Pertussis (Whooping Cough)
714(1)
Tetanus
714(1)
Pneumococcus
714(1)
Meningococcus
715(1)
Active Immunity: Viral Immunizations
715(1)
Hepatitis B
715(1)
PROTOTYPE DRUG: Hepatitis B Vaccine (Engerix-B, Recombivax HB)
716(1)
Hepatitis A
717(1)
Influenza
717(1)
Rabies
717(1)
Measles, Mumps, and Rubella
718(1)
Polio
719(1)
Varicella Zoster
719(1)
Human Papillomavirus
720(1)
Rotavirus
720(1)
Passive Immunity
721(1)
PROTOTYPE DRUG: Rh0[ D] Immune Globulin (RhoGAM)
721(3)
CONNECTIONS: Nursing Practice Application Patients Receiving Immunizations
724(6)
UNIT 7 Pharmacology of the Respiratory System and Allergy
Chapter 44 Pharmacotherapy of Asthma and Other Pulmonary Disorders
730(22)
Physiology of the Lower Respiratory Tract
731(1)
Pathophysiology of Asthma
732(1)
Administration of Pulmonary Drugs via Inhalation
733(1)
Principles of Asthma Pharmacotherapy
734(2)
PROTOTYPE DRUG: Albuterol (Proventil, Ventolin, VoSpire)
736(3)
PROTOTYPE DRUG: Ipratropium (Atrovent)
739(1)
PROTOTYPE DRUG: Beclomethasone (Beconase AQ, Qvar)
740(2)
PROTOTYPE DRUG: Cromolyn
742(1)
PROTOTYPE DRUG: Zafirlukast (Accolate)
743(1)
PROTOTYPE DRUG: Theophylline (Theo-Dur, Others)
744(1)
Chronic Obstructive Pulmonary Disease
745(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Asthma and COPD
746(6)
Chapter 45 Pharmacotherapy of Allergic Rhinitis and the Common Cold
752(22)
Physiology of the Upper Respiratory Tract
753(1)
Pathophysiology of Allergic Rhinitis
754(1)
Pharmacotherapy of Allergic Rhinitis
754(4)
PROTOTYPE DRUG: Fexofenadine (Allegra)
758(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antihistamines
760(2)
PROTOTYPE DRUG: Fluticasone (Flonase, Veramyst)
762(1)
Decongestants
763(1)
PROTOTYPE DRUG: Pseudoephedrine (Sudafed)
763(2)
Drugs for the Common Cold
765(1)
Antitussives
765(1)
PROTOTYPE DRUG: Dextromethorphan (Delsym, Robitussin DM, Others)
766(1)
Expectorants and Mucolytics
767(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Symptomatic Cough and Cold Relief
768(6)
UNIT 8 Pharmacology of Infectious and Neoplastic Diseases
Chapter 46 Basic Principles of Anti-Infective Pharmacotherapy
774(12)
Pathogenicity and Virulence
775(1)
Describing and Classifying Bacteria
776(1)
Classification of Anti-Infectives
776(1)
Mechanisms of Action of Anti-Infectives
776(2)
Inhibition of Cell Wall Synthesis
778(1)
Inhibition of Protein Synthesis
778(1)
Disruption of the Plasma Cell Membrane
778(1)
Inhibition of Nucleic Acid Synthesis
778(1)
Inhibition of Metabolic Pathways (Antimetabolites)
778(1)
Other Mechanisms of Action
778(1)
Acquired Resistance
779(1)
Mechanisms of Resistance
779(1)
Promotion of Resistance
780(1)
Prevention of Resistant Strains
780(2)
Indications and Selection of Specific Anti-Infectives
782(1)
Host Factors Affecting Anti-Infective Selection
783(1)
Host Defenses
783(1)
Local Tissue Conditions
783(1)
Allergy History
783(1)
Other Host Factors
784(1)
Superinfections
784(2)
Chapter 47 Antibiotics Affecting the Bacterial Cell Wall
786(18)
Structure of Bacterial Cell Walls
787(1)
Penicillins
788(2)
Natural Penicillins
790(1)
PROTOTYPE DRUG: Penicillin G
790(1)
Broad-Spectrum Penicillins (Aminopenicillins)
791(1)
PROTOTYPE DRUG: Ampicillin (Principen)
792(1)
Extended-Spectrum (Antipseudomonal) Penicillins
792(1)
Penicillinase-Resistant (Antistaphylococcal) Penicillins
793(1)
Cephalosporins
794(1)
PROTOTYPE DRUG: Cefazolin (Ancef, Kefzol)
795(2)
Carbapenems
797(1)
PROTOTYPE DRUG: Imipenem-Cilastatin (Primaxin)
797(1)
Miscellaneous Cell Wall Inhibitors
798(1)
PROTOTYPE DRUG: Vancomycin (Vancocin)
798(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with a Penicillin, Cephalosporin, or Vancomycin Antibiotic
800(4)
Chapter 48 Antibiotics Affecting Bacterial Protein Synthesis
804(17)
Mechanisms of Antibiotic Inhibition of Bacterial Protein Synthesis
805(1)
Tetracyclines
806(2)
PROTOTYPE DRUG: Tetracycline (Sumycin, Others)
808(1)
Macrolides
809(1)
PROTOTYPE DRUG: Erythromycin (EryC, Erythrocin, Others)
810(2)
Aminoglycosides
812(1)
PROTOTYPE DRUG: Gentamicin (Garamycin, Others)
813(1)
Miscellaneous Inhibitors of Bacterial Protein Synthesis
814(2)
CONNECTIONS: Nursing Practice Application Patients
Receiving Pharmacotherapy with a Tetracycline, Macrolide, or Aminoglycoside Antibiotic
816(5)
Chapter 49 Fluoroquinolones and Miscellaneous Antibacterials
821(12)
Bacterial DNA Replication
822(1)
Inhibition of DNA Replication
822(1)
Fluoroquinolones
823(1)
Adverse Effects
824(1)
PROTOTYPE DRUG: Ciprofloxacin (Cipro)
825(2)
Miscellaneous Antibacterials
827(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Fluoroquinolones
828(5)
Chapter 50 Sulfonamides and the Pharmacotherapy of Urinary Tract Infections
833(15)
Pathophysiology of Urinary Tract Infections
834(1)
Pharmacotherapy of Urinary Tract Infections
834(1)
Acute Uncomplicated Cystitis
834(2)
Complicated Urinary Tract infection
836(1)
Infants and Children
836(1)
Pregnancy
836(1)
Older Adults
837(1)
Recurring Urinary Tract Infections
837(1)
Sulfonamides
837(2)
Adverse Effects
839(1)
PROTOTYPE DRUG: Trimethoprim-Sulfamethoxazole (Bactrim, Septra)
839(2)
Urinary Antiseptics
841(1)
PROTOTYPE DRUG: Nitrofurantoin (Furadantin) and Nitrofurantoin Macrocrystals (Macrobid, Macrodantin)
841(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Urinary Tract Infection
843(5)
Chapter 51 Pharmacotherapy of Mycobacterial Infections
848(18)
Types of Mycobacterial Infections
849(1)
Pathogenesis and Diagnosis of Tuberculosis
849(2)
Pharmacotherapy of Tuberculosis
851(1)
Standard Regimen
852(1)
Patients Who Are HIV Positive
852(2)
Pregnant Patients
854(1)
Chemoprophylaxis Patients
854(1)
PROTOTYPE DRUG: Isoniazid (INH)
855(4)
Drugs for Leprosy
859(1)
PROTOTYPE DRUG: Dapsone (DDS)
859(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Tuberculosis
860(2)
Drugs for Mycobacterium Avium Complex Infections
862(4)
Chapter 52 Pharmacotherapy of Fungal Infections
866(18)
Characteristics of Fungi and Fungal Infections
867(2)
Drugs for Systemic Fungal Infections
869(1)
PROTOTYPE DRUG: Amphotericin B Deoxycholate (Fungizone)
870(2)
Drugs for Both Systemic and Superficial Fungal Infections
872(1)
PROTOTYPE DRUG: Fluconazole (Diflucan)
873(1)
Drugs for Superficial Fungal Infections
874(3)
PROTOTYPE DRUG: Nystatin (Mycostatin, Nystop, Others)
877(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antifungals
879(5)
Chapter 53 Pharmacotherapy of Protozoan and Helminthic Infections
884(22)
Classification and Pathogenesis of Protozoan Infections
885(1)
Drugs for Malaria
886(1)
PROTOTYPE DRUG: Chloroquine (Aralen)
887(3)
Drugs for Nonmalarial Protozoan Infections
890(1)
PROTOTYPE DRUG: Metronidazole (Flagyl)
891(4)
PROTOTYPE DRUG: Pyrimethamine (Daraprim)
895(2)
Classification and Pathogenesis of Helminthic Infections
897(2)
Drugs for Helminthic Infections
899(1)
PROTOTYPE DRUG: Mebendazole (Vermox)
899(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Protozoan and Helminthic Infections
901(5)
Chapter 54 Pharmacotherapy of Non-HIV Viral Infections
906(20)
Characteristics of Viruses
907(2)
Pharmacotherapy of Non-HIV Viral Infections
909(1)
Drugs for Herpesviruses
910(1)
PROTOTYPE DRUG: Acyclovir (Zovirax)
911(2)
Drugs for Influenza Viruses
913(1)
PROTOTYPE DRUG: Amantadine (Symmetrel)
914(1)
Drugs for Hepatitis Viruses
915(4)
PROTOTYPE DRUG: Tenofovir (Viread)
919(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antivirals for Non-HIV Viral Infections
921(5)
Chapter 55 Pharmacotherapy of HIV-AIDS
926(22)
Pathogenesis of HIV Infection
927(2)
General Principles of HIV Pharmacotherapy
929(2)
Classification of Antiretroviral Drugs
931(2)
Antiretroviral Drugs
933(1)
PROTOTYPE DRUG: Zidovudine (Retrovir, AZT)
933(2)
PROTOTYPE DRUG: Efavirenz (Sustiva)
935(2)
PROTOTYPE DRUG: Lopinavir with Ritonavir (Kaletra)
937(2)
Prophylaxis of HIV Infections
939(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antiretrovirals
940(4)
Pharmacotherapy of Opportunistic Infections Associated with HIV-AIDS
944(4)
Chapter 56 Basic Principles of Antineoplastic Therapy
948(14)
Characteristics of Cancer
949(1)
Etiology of Cancer
950(1)
Detection and Prevention of Cancer
950(1)
Goals of Chemotherapy
951(1)
Staging and Grading of Cancer
952(1)
The Cell Cycle and Growth Fraction
952(2)
Cell Kill Hypothesis
954(1)
Improving the Success of Chemotherapy
955(1)
Combination Chemotherapy
955(1)
Dosing Schedules
955(1)
Route of Administration
955(1)
Toxicity of Antineoplastic Agents
956(1)
Hematologic System
957(1)
Gastrointestinal Tract
957(1)
Cardiopulmonary System
958(1)
Urinary System
958(1)
Reproductive System
958(1)
Nervous System
958(1)
Skin and Soft Tissue
958(1)
Other Effects
958(4)
Chapter 57 Pharmacotherapy of Neoplasia
962(34)
Classification of Antineoplastic Drugs
963(1)
Antineoplastic Medications
963(1)
Alkylating Agents
963(1)
PROTOTYPE DRUG: Cyclophosphamide (Cytoxan)
964(4)
Antimetabolites
968(1)
PROTOTYPE DRUG: Methotrexate (MTX, Rheumatrex, Trexall)
969(3)
Antitumor Antibiotics
972(1)
PROTOTYPE DRUG: Doxorubicin (Adriamycin)
973(2)
Hormones and Hormone Antagonists
975(1)
PROTOTYPE DRUG: Tamoxifen
976(4)
Natural Products
980(1)
PROTOTYPE DRUG: Vincristine (Oncovin)
981(2)
Biologic Response Modifiers and Targeted Therapies
983(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Cancer Chemotherapy
983(5)
Miscellaneous Antineoplastics
988(3)
Drugs for Reducing Adverse Effects
991(1)
Preparing and Administering Antineoplastics
992(4)
UNIT 9 Pharmacology of the Gastrointestinal System
Chapter 58 Review of the Gastrointestinal System
996(8)
Overview of the Digestive System
997(1)
Physiology of the Upper Gastrointestinal Tract
997(2)
Physiology of the Lower Gastrointestinal Tract
999(1)
Physiology of the Accessory Organs of Digestion
1000(1)
Regulation of Digestive Processes
1001(1)
Nutrient Categories and Metabolism
1002(2)
Chapter 59 Pharmacotherapy of Peptic Ulcer Disease
1004(19)
Physiology of the Upper Gastrointestinal Tract
1005(1)
Etiology and Pathogenesis of Peptic Ulcer Disease
1005(3)
Etiology and Pathogenesis of Gastroesophageal Reflux Disease
1008(1)
Pharmacotherapy of Peptic Ulcer Disease and Gastroesophageal Reflux Disease
1008(2)
Pharmacotherapy with Proton Pump Inhibitors
1010(1)
PROTOTYPE DRUG: Omeprazole (Prilosec)
1011(2)
Pharmacotherapy with H2-Receptor Antagonists
1013(1)
PROTOTYPE DRUG: Ranitidine (Zantac)
1014(1)
Pharmacotherapy with Antacids
1015(1)
PROTOTYPE DRUG: Aluminum Hydroxide (AlternaGEL, Others)
1016(1)
Pharmacotherapy of Helicobacter pylori Infection
1017(1)
Miscellaneous Drugs Used for Peptic Ulcer Disease and Gastroesophageal Reflux Disease
1018(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Peptic Ulcer Disease
1019(4)
Chapter 60 Pharmacotherapy of Bowel Disorders and Other Gastrointestinal Conditions
1023(24)
Pathophysiology of Constipation
1024(1)
Pharmacotherapy with Laxatives
1025(1)
PROTOTYPE DRUG: Psyllium Mucilloid (Metamucil, Others)
1026(1)
Pathophysiology of Diarrhea
1027(1)
Pharmacotherapy of Diarrhea
1028(1)
PROTOTYPE DRUG: Diphenoxylate with Atropine (Lomotil)
1029(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Laxatives or Antidiarrheals
1030(1)
Pharmacotherapy of Inflammatory Bowel Disease
1030(3)
PROTOTYPE DRUG: Sulfasalazine (Azulfidine)
1033(2)
Pharmacotherapy of Irritable Bowel Syndrome
1035(1)
Pathophysiology of Nausea and Vomiting
1036(1)
Pharmacotherapy of Nausea and Vomiting
1037(3)
PROTOTYPE DRUG: Ondansetron (Zofran, Zuplenz)
1040(1)
Pharmacotherapy of Pancreatitis
1041(1)
PROTOTYPE DRUG: Pancrelipase (Creon, Pancreaze, Zenpep)
1041(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antiemetics
1042(5)
Chapter 61 Vitamins and Minerals
1047(15)
Role of Vitamins in Health and Disease
1048(1)
Regulation of Vitamins
1049(1)
Recommended Dietary Allowance
1050(1)
Fat-Soluble Vitamins
1051(1)
Vitamin A (Aquasol A)
1051(1)
Vitamin D (Calcijex, Rocaltrol)
1051(1)
Vitamin E (Aquasol E, Vita-Plus E, Others)
1052(1)
Vitamin K (AquaMEPHYTON)
1053(1)
Water-Soluble Vitamins
1053(1)
Thiamine: Vitamin B1
1053(1)
Riboflavin: Vitamin B2
1054(1)
Niacin: Vitamin B3
1054(1)
Pyridoxine: Vitamin B6
1054(1)
Folic Acid: Vitamin B9
1055(1)
Cyanocobalamin: Vitamin B12
1055(1)
Vitamin C: Ascorbic Acid
1056(1)
Minerals
1056(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Vitamin or Mineral Supplements
1058(4)
Chapter 62 Enteral and Parenteral Nutrition
1062(16)
Enteral Nutrition
1063(1)
Methods of Administration
1064(1)
Enteral Formulations
1064(1)
Elements of Enteral Nutrition
1065(1)
Complications of Enteral Therapy
1065(3)
Drug and Food Interactions
1068(1)
Parenteral Nutrition
1069(1)
Components of Total Parenteral Nutrition Solutions
1070(1)
Complications of Parenteral Therapy
1071(1)
Drug and Food Interactions
1072(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Enteral and Parenteral Nutrition
1073(5)
Chapter 63 Weight Reduction Strategies and the Pharmacotherapy of Obesity
1078(12)
Etiology of Obesity
1079(1)
Pathogenesis of Obesity
1079(1)
Measurement of Obesity
1080(1)
Nonpharmacologic Therapies for Obesity
1080(2)
Pharmacotherapy of Obesity
1082(1)
PROTOTYPE DRUG: Orlistat (Alli, Xenical)
1082(3)
Adjuncts to Obesity Therapy
1085(5)
UNIT 10 Pharmacology of the Endocrine System
Chapter 64 Review of the Endocrine System
1090(6)
Overview of the Endocrine System
1091(1)
Hormone Receptors
1091(1)
Negative Feedback Mechanisms
1091(2)
Hormone Pharmacotherapy
1093(3)
Chapter 65 Hypothalamic and Pituitary Drugs
1096(15)
Functions of the Hypothalamus
1097(1)
Functions of the Pituitary Gland
1098(1)
Pharmacotherapy of Growth Hormone Disorders
1098(1)
PROTOTYPE DRUG: Somatropin (Genotropin, Humatrope, Norditropin, Nutropin, Saizen, Serostim, Zorbtive)
1099(3)
PROTOTYPE DRUG: Octreotide (Sandostatin)
1102(1)
Pharmacotherapy of Antidiuretic Hormone Disorders
1103(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Growth Hormone
1104(2)
PROTOTYPE DRUG: Desmopressin (DDAVP)
1106(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antidiuretic Hormone
1107(4)
Chapter 66 Pharmacotherapy of Diabetes Mellitus
1111(26)
Physiology of Serum Glucose Control
1112(1)
Pathophysiology of Diabetes Mellitus: Types of Diabetes
1113(1)
Symptoms and Diagnosis of Diabetes
1114(1)
Complications of Diabetes Mellitus
1114(1)
PROTOTYPE DRUG: Glucagon (GlucaGen)
1115(2)
Insulin Therapy
1117(1)
Insulin Adjunct
1118(1)
PROTOTYPE DRUG: Human Regular Insulin (Humulin R, Novolin R)
1119(2)
Antidiabetic Drugs for Type 2 Diabetes
1121(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Insulin
1122(3)
Sulfonylureas
1125(1)
PROTOTYPE DRUG: Glyburide (DiaBeta, Glynase, Micronase)
1125(1)
Biguanides
1126(1)
PROTOTYPE DRUG: Metformin (Glucophage, Glumetza, Others)
1126(1)
Meglitinides
1127(1)
PROTOTYPE DRUG: Repaglinide (Prandin)
1127(1)
Thiazolidinediones
1128(1)
PROTOTYPE DRUG: Rosiglitazone (Avandia)
1128(1)
Alpha-Glucosidase Inhibitors
1129(1)
PROTOTYPE DRUG: Acarbose (Precose)
1129(1)
Incretin Enhancers
1130(1)
PROTOTYPE DRUG: Sitagliptin (Januvia)
1130(1)
Miscellaneous Antidiabetic Drugs
1131(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Type 2 Diabetes
1132(5)
Chapter 67 Pharmacotherapy of Thyroid Disorders
1137(14)
Physiology of the Thyroid Gland
1138(1)
Diagnosis of Thyroid Disorders
1139(1)
Hypothyroid Disorders
1140(1)
Pharmacotherapy of Hypothyroid Disorders
1140(1)
PROTOTYPE DRUG: Levothyroxine (Levothroid, Levoxyl, Synthroid, Unithroid)
1141(1)
Hyperthyroid Disorders
1142(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Thyroid Hormone Replacements
1143(2)
Pharmacotherapy of Hyperthyroid Disorders
1145(1)
PROTOTYPE DRUG: Propylthiouracil (PTU)
1145(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Antithyroid Drugs
1147(4)
Chapter 68 Corticosteroids and Drugs Affecting the Adrenal Cortex
1151(15)
Physiology of the Adrenal Gland
1152(1)
Overview of Corticosteroid Pharmacotherapy
1153(1)
Adverse Effects of Corticosteroids
1154(1)
Replacement Therapy with Corticosteroids
1155(2)
PROTOTYPE DRUG: Hydrocortisone (Cortef, Solu-Cortef, Others)
1157(1)
Corticosteroids for Nonendocrine Conditions
1158(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Systemic Corticosteroids
1160(2)
Mineralocorticoids
1162(1)
PROTOTYPE DRUG: Fludrocortisone
1162(1)
Antiadrenal Drugs
1163(3)
Chapter 69 Estrogens, Progestins, and Drugs Modifying Uterine Function
1166(23)
Hormonal Regulation of Female Reproductive Function
1167(1)
Estrogens
1167(1)
PROTOTYPE DRUG: Conjugated Estrogens (Cenestin, Enjuvia, Premarin)
1168(3)
Progestins
1171(1)
PROTOTYPE DRUG: Medroxyprogesterone (Depo-Provera, Depo-SubQ-Provera, Provera)
1171(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Estrogen
1172(2)
Hormone Replacement Therapy
1174(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Progestin
1175(1)
Uterine Stimulants: Oxytocics
1176(1)
PROTOTYPE DRUG: Oxytocin (Pitocin)
1177(2)
Uterine Relaxants: Tocolytics
1179(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Oxytocin (Pitocin)
1180(1)
Pharmacotherapy of Female Infertility
1181(2)
PROTOTYPE DRUG: Clomiphene (Clomid, Serophene)
1183(6)
Chapter 70 Drugs for Modifying Conception
1189(19)
Options and Choices for Birth Control
1190(1)
Combination Oral Contraceptives
1190(4)
PROTOTYPE DRUG: Estradiol and Norethindrone (Ortho-Novum, Others)
1194(1)
Progestin-Only Oral Contraceptives
1195(1)
Adverse Effects of Combined Oral Contraceptives
1196(1)
Drugs for Long-Term Contraception and Newer Contraceptive Delivery Methods
1197(2)
Spermicides
1199(1)
PROTOTYPE DRUG: Nonoxynol-9
1200(1)
Emergency Contraception
1200(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Hormonal Contraceptives
1201(1)
Drugs for Pharmacologic Abortion
1202(1)
PROTOTYPE DRUG: Mifepristone (Mifeprex)
1203(5)
Chapter 71 Drugs for Disorders and Conditions of the Male Reproductive System
1208(20)
Regulation of Male Reproductive Function
1209(1)
Pharmacotherapy with Androgens
1210(1)
PROTOTYPE DRUG: Testosterone
1211(1)
Anabolic Steroids
1212(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy with Androgens
1213(1)
Etiology of Male Sexual Dysfunction
1214(1)
Pharmacotherapy of Male Infertility
1215(1)
Pharmacotherapy of Erectile Dysfunction
1216(2)
PROTOTYPE DRUG: Sildenafil (Viagra)
1218(1)
Pathophysiology of Benign Prostatic Hyperplasia
1219(1)
Pharmacotherapy of Benign Prostatic Hyperplasia
1220(1)
PROTOTYPE DRUG: Finasteride (Proscar)
1221(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Benign Prostatic Hyperplasia
1223(5)
UNIT 11 Additional Drug Classes
Chapter 72 Pharmacotherapy of Bone and Joint Disorders
1228(33)
Role of Calcium in Body Homeostasis
1229(1)
Regulation of Calcium Balance
1230(2)
Pharmacotherapy of Hypocalcemia
1232(1)
PROTOTYPE DRUG: Calcium Salts
1232(1)
Pathophysiology of Metabolic Bone Disease
1233(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Osteoporosis
1234(3)
Pharmacotherapy of Metabolic Bone Disease
1237(1)
PROTOTYPE DRUG: Calcitriol (Calcijet, Rocaltrol)
1237(3)
PROTOTYPE DRUG: Alendronate (Fosamax)
1240(2)
PROTOTYPE DRUG: Raloxifene (Evista)
1242(2)
Pathophysiology and Pharmacotherapy of Joint Disorders
1244(5)
PROTOTYPE DRUG: Hydroxychloroquine (Plaquenil)
1249(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Rheumatoid Arthritis and Osteoarthritis
1251(2)
Pharmacotherapy of Gout and Hyperuricemia
1253(1)
PROTOTYPE DRUG: Colchicine (Colcrys)
1253(2)
PROTOTYPE DRUG: Allopurinol (Lopurin, Zyloprim)
1255(2)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Gout
1257(4)
Chapter 73 Pharmacotherapy of Dermatologic Disorders
1261(22)
Anatomy of the Integumentary System
1262(1)
Classification of Skin Disorders
1263(1)
Pharmacotherapy of Skin Infections
1264(1)
Scabicides and Pediculicides
1265(1)
PROTOTYPE DRUG: Permethrin (Acticin, Elimite, Nix)
1265(1)
Pharmacotherapy of Acne and Rosacea
1266(1)
Acne Vulgaris
1267(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Lice or Mite Infestation
1267(2)
Rosacea
1269(1)
PROTOTYPE DRUG: Tretinoin (Avita, Retin-A, Others)
1269(2)
Pharmacotherapy of Dermatitis
1271(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Acne and Related Skin Conditions
1271(3)
Pharmacotherapy of Psoriasis
1274(1)
Topical Drugs
1274(1)
Systemic Drugs
1275(2)
Pharmacotherapy of Minor Skin Burns
1277(1)
PROTOTYPE DRUG: Benzocaine (Americaine, Anbesol, Others)
1278(1)
Pharmacotherapy of Alopecia
1279(4)
Chapter 74 Pharmacotherapy of Eye and Ear Disorders
1283(19)
Anatomy of the Eye
1284(2)
Pathophysiology of Glaucoma
1286(1)
Pharmacotherapy of Glaucoma
1286(1)
PROTOTYPE DRUG: Latanoprost (Xalatan)
1287(3)
PROTOTYPE DRUG: Timolol (Betimol, Timoptic, Others)
1290(1)
CONNECTIONS: Nursing Practice Application Patients
Receiving Pharmacotherapy for Glaucoma
1291(1)
Miscellaneous Drugs for Treating Glaucoma
1292(1)
Pharmacotherapy for Eye Examinations
1292(2)
Pharmacotherapy for Other Eye Conditions
1294(1)
Anatomy of the Ear
1295(1)
Pharmacotherapy with Otic Preparations
1295(3)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Otitis
1298(4)
Chapter 75 Emergency Preparedness: Bioterrorism and Management of Poisoning
1302(14)
Emergency Preparedness, Bioterrorism, and Nursing
1303(2)
Biologic Agents
1305(1)
Chemical and Physical Agents
1306(2)
Management of Poisoning
1308(1)
PROTOTYPE DRUG: Activated Charcoal (CharcoAid)
1309(1)
PROTOTYPE DRUG: Edetate Calcium Disodium (Calcium EDTA)
1310(1)
PROTOTYPE DRUG: Dimercaprol (BAL in Oil)
1311(1)
CONNECTIONS: Nursing Practice Application Patients Receiving Pharmacotherapy for Poisoning or Overdose
1312(4)
Appendices
A Answers to
Chapter Review
1316(27)
B ISMP List of High-Alert Medications in Acute Care Settings
1343(1)
Glossary 1344(18)
Credits 1362(1)
Index 1363
Michael Patrick Adams, PhD, is an accomplished educator, author, and national speaker. The National Institute for Staff and Organizational Development in Austin, Texas, named Dr. Adams a Master Teacher. He has published two other textbooks with Pearson Education: Core Concepts in Pharmacology and Pharmacology for Nurses: A Pathophysiologic Approach.

 

Dr. Adams obtained his masters degree in pharmacology from Michigan State University and his doctorate in education from the University of South Florida. Dr. Adams was on the faculty of Lansing Community College and St. Petersburg College, and was Dean of Health Programs at Pasco-Hernando Community College for 15 years. He is currently Professor of Biological Sciences at Pasco-Hernando Community College.



Carol Quam Urban, PhD, RN, is the Assistant Dean for Undergraduate Nursing and an Assistant Professor in the School of Nursing, College of Health and Human Services, at George Mason University in Fairfax, Virginia. She teaches pharmacology and pathophysiology and serves as a doctoral advisor for students in administrative practicum experiences, as well as Chair and Reader on dissertation committees. At Mason, she serves on the Distance Education Council and the General Education Committee and has presented on Lessons Learned: Launching a Fully Online RN-to-BSN Pathway. She has published the Pearson textbook Pharmacology for Nurses: A Pathophysiologic Approach with Dr. Adams and Dr. Holland.